These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The role of Denosumab in joint preservation for patients with giant cell tumour of bone. Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS. Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180 [Abstract] [Full Text] [Related]
24. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab]. Gong LH, Liu WF, Ding Y, Zhang W, Yang YK, Yu F, Wong GQ, Huang XY, Niu XH. Zhonghua Bing Li Xue Za Zhi; 2018 Jun 08; 47(6):449-454. PubMed ID: 29886590 [Abstract] [Full Text] [Related]
30. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T. J Orthop Surg (Hong Kong); 2020 Jun 08; 28(2):2309499020929786. PubMed ID: 32539628 [Abstract] [Full Text] [Related]
31. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence? Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, Franchi A, Capanna R, Campanacci DA. Clin Orthop Relat Res; 2018 Sep 08; 476(9):1783-1790. PubMed ID: 30778015 [Abstract] [Full Text] [Related]
32. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center. Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W. J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187 [Abstract] [Full Text] [Related]
33. Current concepts in the treatment of giant cell tumour of bone. van der Heijden L, Dijkstra S, van de Sande M, Gelderblom H. Curr Opin Oncol; 2020 Jul 17; 32(4):332-338. PubMed ID: 32541321 [Abstract] [Full Text] [Related]
35. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Arch Orthop Trauma Surg; 2019 Oct 17; 139(10):1339-1349. PubMed ID: 30877429 [Abstract] [Full Text] [Related]
36. Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. Boye K, Jebsen NL, Zaikova O, Knobel H, Løndalen AM, Trovik CS, Monge OR, Hall KS. Acta Oncol; 2017 Mar 17; 56(3):479-483. PubMed ID: 28105885 [Abstract] [Full Text] [Related]
38. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India. Rekhi B, Verma V, Gulia A, Jambhekar NA, Desai S, Juvekar SL, Bajpai J, Puri A. Pathol Oncol Res; 2017 Jan 17; 23(1):157-164. PubMed ID: 27722984 [Abstract] [Full Text] [Related]
39. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS. Clin Orthop Relat Res; 2020 Nov 17; 478(11):2522-2533. PubMed ID: 32401001 [Abstract] [Full Text] [Related]